NanoViricides Announces Breakthrough in RSV Treatment with NV-387

NanoViricides, Inc., a pioneer in nanomedicine antiviral therapies, reported a significant breakthrough in treating Respiratory Syncytial Virus (RSV) with its novel drug, NV-387. Recent studies have shown NV-387 to deliver complete survival rates in lethally infected animal models, vastly outperforming the current standard treatment, ribavirin.

The study documented that NV-387, when administered orally across 11 doses, led to 100% survival of mice infected with a lethal dose of RSV over a 21-day period. This compares starkly to ribavirin-treated animals, all of which succumbed by day 14. This positions NV-387 as a potentially superior option to ribavirin, which is hindered by significant toxicity issues and limited use in emergencies.

RSV represents a major health risk particularly to young children and the elderly, with substantial hospitalization rates annually. The urgency for an effective treatment is compounded by the lack of viable pharmaceutical options, beyond ribavirin and recent prophylactic vaccines for older populations. NV-387 not only promises a significant leap in treating RSV but demonstrates versatility against a range of respiratory viruses, including COVID-19 and influenza.

According to Dr. Anil R. Diwan, President and Chairman of NanoViricides, the success of NV-387 in such lethal infection models indicates extraordinary efficacy, suggesting a paradigm shift in managing viral infections with potentially broad implications for global public health.